Using Interrupted Time Series Analysis to Measure the Impact of Legalized Syringe Exchange on HIV Diagnoses in Baltimore and Philadelphia: Erratum
In the December 1, 2019 Supplement 2 of JAIDS Journal of Acquired Immune Deficiency Syndromes, in the article titled “Using Interrupted Time Series Analysis to Measure the Impact of Legalized Syringe Exchange on HIV Diagnoses in Baltimore and Philadelphia”, the authors mistakenly reported the estimated cost savings for Baltimore to be $62.4 million annually and $624 million over 10 years, and the 1-year return on investment (ROI) factoring in the cost of syringe exchange programs to be $46.8 million. The correct cost savings estimates are $43.4 million annually and $434.3 million over 10 years, and the correct 1-year ROI estimate is $32 million.
Additionally, in the acknowledgments section, Dr. C. Patrick Chaulk’s affiliation should be Former Assistant Commissioner for STD/HIV Services and Adjunct Faculty at Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health.
Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.
Ruiz MS, O’Rourke A, Allen AT, et al. Using interrupted time series analysis to measure the impact of legalized syringe exchange on HIV diagnoses in Baltimore and Philadelphia. J Acquir Immune Defic Syndr 2019;82(4)(suppl 2):S148-S154. doi: 10.1097/QAI.0000000000002176.